Some human B cell lymphomas, as is the case of Burkitt lymphoma and a fraction of Diffuse Large B cell lymphomas, carry alterations in the MYC gene. Presence of these genetic alterations leads to the onset of aggressive lymphomas, which require treatment with very intensive and toxic chemotherapeutic regimes, and are often associated to rather poor clinical outcomes. Many research efforts have been dedicated to understand how MYC gene alterations associate to these aggressive features, and it is believed that targeting the activity of this gene can significantly improve patient outcome or provide a means for a cure. An important strategy to do this is the generation of animal models that closely reproduce these human lymphomas, where to learn more about their biology, natural history, and find and test alternative treatments that could significantly improve or surpass current strategies. This project aims to generate and characterize a new model for these specific types of aggressive lymphomas. Different from previous imprecise models of these cancers, it provides a faithful replica of the detailed circumstances underlying their origin. Validation of this model can help fulfill all these expectations, and impact how we understand and manage these diseases.
|Effective start/end date||1/01/16 → 31/12/17|
- Leukemia Research Foundation: $100,000.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.